November 27, 2017
Appointment of Non-executive Director

27 November 2017

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.

Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.

Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans."

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.

For further information contact:

BTG

Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

FTI Consulting

Ben Atwell/Simon Conway
+44 (0)20 3727 1000

About BTG

BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.